This observational, retrospective study aims to understand the treatment patterns and outcomes of patients with pulmonary and extra-pulmonary neuroendocrine carcinomas (NEC) in Latin America (Brazil, Mexico, Argentina, and Peru). The research will collect data from medical records to analyze factors like patient demographics, diagnosis methods, tumor characteristics, treatment approaches, and disease progression. The study is non-interventional, meaning patient care will follow standard clinical practice, with data gathered via an electronic system.
Currently, there is a hypothesis that there is not enough evidence to fully understand the patient journey and accurately determine the clinical outcomes of neuroendocrine carcinomas (NEC) in Latin America. A better understanding of this landscape, including its unique regional aspects, could lead to improved patient care. To address this gap, this observational, retrospective, non-interventional study aims to describe treatment patterns and outcomes for patients with both pulmonary and extra-pulmonary NEC in Latin America. Eligible patients diagnosed with either form of NEC will be included, and data will be collected from medical records at selected sites across Brazil, Mexico, Argentina, and Peru. Data to be retrieved include but are not limited to age at diagnosis, gender, ECOG at diagnosis, stage (TNM), resources used for primary diagnosis (imaging, upfront surgery etc.), primary site, tumor size and grade, setting of initial treatment (reference center vs community hospital), type of initial surgical approach, data of anti-cancer treatments (including (neo)adjuvant and advanced settings) and relapse and/or progression/death. Data regarding anti-cancer treatments (including (neo)adjuvant and advanced settings), as well as radiotherapy use will also be recorded. As this project is non-interventional, patients will still receive treatment and clinical assessments for extra-pulmonary and pulmonary NEC as determined by their attending physician, according to the standard of care and routine clinical practice at each site. No visits are demanded by the study, but for those required for the consent process whenever determined by the local ethics committee. Patient source data will be taken from the patient's medical records and reported by means of an electronic data capture (EDC) system.
Study Type
OBSERVATIONAL
Enrollment
200
This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Hospital Británico de Buenos Aires
Buenos Aires, Buenos Aires, Argentina
RECRUITINGHospital de Gastroenterología Carlos Bonorino Udaondo
Buenos Aires, Buenos Aires, Argentina
RECRUITINGInstituto Alexander Fleming
Buenos Aires, Buenos Aires, Argentina
RECRUITINGHospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
Cachoeiro de Itapemirim, Espírito Santo, Brazil
ACTIVE_NOT_RECRUITINGClínica Prognóstica - Centro de Pesquisa Clínica Onconeo
Campo Grande, Mato Grosso do Sul, Brazil
ACTIVE_NOT_RECRUITINGOncocentro de Minas Gerais (Oncoclínicas)
Belo Horizonte, Minas Gerais, Brazil
ACTIVE_NOT_RECRUITINGIOP Pesquisa - Instituto de Oncologia do Paraná
Curitiba, Paraná, Brazil
ACTIVE_NOT_RECRUITINGHCL - Hospital do Câncer de Londrina
Londrina, Paraná, Brazil
ACTIVE_NOT_RECRUITINGINCA - Instituto Nacional de Câncer
Rio de Janeiro, Rio de Janeiro, Brazil
ACTIVE_NOT_RECRUITINGHUOL - Hospital Universitário Onofre Lopes da UFRN
Natal, Rio Grande do Norte, Brazil
ACTIVE_NOT_RECRUITING...and 9 more locations
Patterns of Initial Cancer Treatment: number of participants treated within vs. outside high-volume sites and associated treatment characteristics
Treatment patterns will be analyzed descriptively using tables and graphs to illustrate the distribution of patients receiving initial cancer treatment within versus outside high-volume treatment centers. Key characteristics of the initial treatment will be assessed.
Time frame: Throughout the study period, an average of 24 months
Event-free survival (EFS)
defined as time from diagnosis until relapse, death, or definitive failure of treatment strategy that implicates failure of curative-intent treatment \[for patients treated with curative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
Time frame: Throughout the study period, an average of 24 months
Time to treatment failure (TTF)
in first and second-line: defined as time from first dose of treatments until date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death. Participants who are lost to follow up or reach the study end will be censored at their last date of contact
Time frame: Throughout the study period, an average of 24 months
Progression-free survival (PFS)
defined as time from treatment initiation until progression or death \[for patients treated with palliative intent\]. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
Time frame: Throughout the study period, an average of 24 months
Overall survival
\[according to disease stage/setting\], defined as time from initial diagnosis until date of death from any cause. Participants who are lost to follow up or reach the study end will be censored at their last date of contact.
Time frame: Throughout the study period, an average of 24 months
Frequency of DLL-3 immunohistochemistry expression
Rate of patients with DLL3 expression in extra-pulmonary and pulmonary NEC by IHC \[stratified by tumor primary site\]
Time frame: After the end of recruitment, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.